New hope for kids with tough cancer: drug combo trial launches
NCT ID NCT07537400
First seen Apr 19, 2026 · Last updated May 17, 2026 · Updated 5 times
Summary
This study tests whether adding the drug naxitamab to standard chemotherapy is safe and effective for children and young adults (ages 1 to 21) newly diagnosed with high-risk neuroblastoma, an aggressive nerve cancer. Ten participants will receive the combination during initial treatment. The goal is to see if this approach improves tumor shrinkage and reduces the chance of the cancer returning, while carefully monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shaare Zedek Medical Center
Jerusalem, Israel
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.